UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000002477
Receipt No. R000003036
Scientific Title Drug-drug interaction study to explore importance of CYP3A4 and OATP1B1 as factors determining pharmacokinetics of atorvastatin
Date of disclosure of the study information 2009/09/10
Last modified on 2012/07/13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Drug-drug interaction study to explore
importance of CYP3A4 and OATP1B1 as factors determining pharmacokinetics of atorvastatin
Acronym Drug-drug interaction study on atorvastatin
Scientific Title Drug-drug interaction study to explore
importance of CYP3A4 and OATP1B1 as factors determining pharmacokinetics of atorvastatin
Scientific Title:Acronym Drug-drug interaction study on atorvastatin
Region
Japan

Condition
Condition healthy male subjects
Classification by specialty
Not applicable
Classification by malignancy Others
Genomic information YES

Objectives
Narrative objectives1 To examine the effects of functional variation of OATP1B1and CYP3A4 on pharmacokinetics of atorvastatin in japanese healthy subjects by using microdose.
Basic objectives2 Others
Basic objectives -Others gene analysis
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes pharmacokinetic of atorvastatin
Key secondary outcomes pharmacokinetics of midazolam, pravastatin, itraconazole and rifampicin
gene analysis

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Drug administration(microdose of atorvastatin,midazolam,pravastatin)->(over 1week for washout)->Drug administration(clinical dose of rifampicin,microdose of atorvastatin, midazolam,pravastatin)->(over 1week for washout)->Drug administration(clinical dose of itraconazole,microdose of atorvasutatin, midazolam, pravastatin)
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
40 years-old >
Gender Male
Key inclusion criteria 1)Ability to understand and willing to sign the informed consent.
2)Japanese healthy male subjects age 20 to 40 years of age
3)Weight between 50-100kg.
4)Healthy subject as determined by medical history, physical examination, ECGs, and clinical laboratory tests.
Key exclusion criteria 1)Any hypersensitivities to atorvastatin,midazolam,pravastatin, straconazole or rifampicin.
2)hepatic disease requiring treatment.
3)acute narrow-angle glaucoma
4)QT prolongation over 460ms.
5)Use of medicine or health product including Saint John's wort 2 weeks before pre-dose.
6)Intake of fruit food and drink including grapefruit juice, orange juice or apple juice from 7 days before pre-dose.
7)Participation to any other clinical reseach in the past 3 months.
8)Donating over 200 ml of blood in the past 1 month or over 400ml of blood in the past 3 months.
9)Positive tests of serological reaction for syphilis, HIV antigen and antibody, HBs antigen or HCV antibody.
10)Any allergy to drug and food
11)Drug abuse or positive drug screening
12)Any condition that, in the opinion of the investigator, would make the patient unsuitable for the study.
Target sample size 8

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yuji Kumagai
Organization Kitsato University East Hospital
Division name Clinical trial Center
Zip code
Address 2-1-1, Asamizodai, Sagamihara, Kanagawa, 228-8520
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name
Organization Kitsato University East Hospital
Division name Clinical trial Center
Zip code
Address 2-1-1, Asamizodai, Sagamihara, Kanagawa, 228-8520
TEL
Homepage URL
Email

Sponsor
Institute Clinical trial Center,Kitsato University East Hospital
Institute
Department

Funding Source
Organization APDD, Association for Promoting Drug Development
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2009 Year 09 Month 10 Day

Related information
URL releasing protocol
Publication of results Partially published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2009 Year 08 Month 30 Day
Date of IRB
Anticipated trial start date
2009 Year 09 Month 01 Day
Last follow-up date
2009 Year 11 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2009 Year 09 Month 10 Day
Last modified on
2012 Year 07 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003036

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.